SYNLAB Future Growth

Future criteria checks 4/6

SYNLAB is forecast to grow earnings and revenue by 36.4% and 7.5% per annum respectively. EPS is expected to decline by 14.5% per annum. Return on equity is forecast to be 2.9% in 3 years.

Key information

36.4%

Earnings growth rate

-14.5%

EPS growth rate

Healthcare earnings growth	23.2%
Revenue growth rate	7.5%
Future return on equity	2.9%
Analyst coverage	Low
Last updated	01 May 2024

Recent future growth updates

Recent updates

SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger

Dec 15

Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)

Sep 10

SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 14

SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market

May 29

Earnings and Revenue Growth Forecasts

DB:SYAB - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	3,314	253	N/A	N/A	1
12/31/2025	3,103	69	130	409	2
12/31/2024	2,914	91	95	372	2
12/31/2023	2,635	92	237	363	N/A
9/30/2023	2,691	129	138	303	N/A
6/30/2023	2,772	69	216	374	N/A
3/31/2023	2,892	-37	305	461	N/A
12/31/2022	3,251	151	471	630	N/A
9/30/2022	3,542	345	614	774	N/A
6/30/2022	3,693	404	714	872	N/A
3/31/2022	3,888	653	848	1,001	N/A
12/31/2021	3,765	608	867	1,012	N/A
9/30/2021	3,703	591	965	1,085	N/A
6/30/2021	3,561	385	816	929	N/A
3/31/2021	3,080	225	590	692	N/A
12/31/2020	2,621	36	426	520	N/A
12/31/2019	1,906	-122	289	360	N/A
12/31/2018	1,808	-51	253	339	N/A
12/31/2017	1,817	-166	136	213	N/A
12/31/2016	1,570	-230	N/A	232	N/A
12/31/2015	845	-169	N/A	7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYAB's forecast earnings growth (36.4% per year) is above the savings rate (0.7%).

Earnings vs Market: SYAB's earnings (36.4% per year) are forecast to grow faster than the German market (15.9% per year).

High Growth Earnings: SYAB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SYAB's revenue (7.5% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: SYAB's revenue (7.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SYAB's Return on Equity is forecast to be low in 3 years time (2.9%).

SYNLAB Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target increased by 9.8% to €11.93

Price target increased by 8.2% to €11.44

Consensus EPS estimates fall by 14%

Consensus EPS estimates fall by 26%

Consensus EPS estimates fall by 18%

Price target decreased by 11% to €15.62

Recent updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 9.8% to €11.93

SYNLAB AG to Report Q3, 2024 Results on Nov 07, 2024

Third quarter 2023 earnings released: EPS: €0.59 (vs €0.31 in 3Q 2022)

Synlab Launches Revolutionary Bipolar Disorder Diagnostic Test

SYNLAB AG to Report Fiscal Year 2023 Results on Mar 25, 2024

Investor sentiment improves as stock rises 17%

Price target increased by 8.2% to €11.44

New major risk - Financial position

Second quarter 2023 earnings released: EPS: €0.053 (vs €0.42 loss in 2Q 2022)

SYNLAB AG Provides Significant Support for the Largest Ever Multi-National Study on Cholesterol

Upcoming dividend of €0.33 per share at 3.3% yield

Consensus EPS estimates fall by 14%

Full year 2022 earnings: Revenues in line with analyst expectations

Consensus EPS estimates fall by 26%

Investor sentiment improves as stock rises 31%

Consensus EPS estimates fall by 18%

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 11% to €15.62

Price target decreased to €16.84

SYNLAB AG, Annual General Meeting, May 17, 2023

Price target decreased to €17.08

Investor sentiment deteriorated over the past week

SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger

Price target decreased to €17.51

Price target decreased to €18.26

Price target decreased to €18.96

SYNLAB AG (DB:SYAB) announces an Equity Buyback for 1,860,647 shares, for €31.63 million.

Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Second quarter 2022 earnings released

Consensus EPS estimates increase by 14%

SYNLAB AG Revises Earnings Guidance for the Fiscal Year 2022

SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

SYNLAB (FRA:SYAB) Is Investing Its Capital With Increasing Efficiency

Investor sentiment improved over the past week

SYNLAB AG Revises Earnings Guidance for 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

SYNLAB AG (DB:SYAB) acquired Sistemas Genomicos S.L. from Ascires Biomedical Group.

Are Investors Undervaluing SYNLAB AG (FRA:SYAB) By 25%?

Shareholders Will Be Pleased With The Quality of SYNLAB's (FRA:SYAB) Earnings

SYNLAB AG (DB:SYAB) agreed to acquire Laboratorio Médico Polanco and Laboratorio Clinicos de Puebla from Médica Sur, S.A.B. de C.V. (BMV:MEDICA B).

SYNLAB AG Provides Screenings for Pupils in North Rhine-Westphalia with the So-Called Lollipop-PCR-Tests

Synlab Introduces New PCR Pooling Test Method for Companies

SYNLAB AG has completed an IPO in the amount of €1.11875 billion.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies